Amro Elshoury, MD
Hematology & Oncology · Indianapolis, INNPI 1417398975
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $182,356 of the $211,801 with a category attached, or 86.1%. Blueprint Medicines Corporation accounts for 98.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $107,086 and has fallen 97.7% since, to $2,464 in 2025. Among hematology & oncology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $994.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$209K
- Bristol Myers Squibb$2K
- Akebia Therapeutics Inc$450
- Vertex$433
- Biomarin Pharmaceutical Inc.$46
- Takeda Pharmaceuticals U.S.A., Inc.$33
- plus $72 from 3 others
Across 21 payments — averaging $9630.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Blueprint Medicines Corporation$188K
- AbbVie$14K
What the payments were for
- Consulting fees$2,5461%
- Speaking & faculty fees$182,35686%
- Travel & lodging$23,73711%
- Food & beverage$3,1321%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 203 | $209,105 |
| Bristol Myers Squibb | 1 | $1,663 |
| Akebia Therapeutics Inc | 1 | $450 |
| Vertex | 1 | $433 |
| Biomarin Pharmaceutical Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Pfizer | 1 | $26 |
| Agios Pharmaceuticals, Inc. | 1 | $24 |
| Servier Pharmaceuticals LLC | 2 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$211,801 in reported general payments places this provider in the 95th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Indianapolis
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
- Daniel MiltonIndianapolis$231K
- Brian MulherinIndianapolis$175K
- Muhammad Sarfraz NawazIndianapolis$172K
- John EdwardsIndianapolis$169K
- Karam Al-IssaIndianapolis$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.